{
    "organizations": [],
    "uuid": "4b1a9b3bd7f5f032c545b10ce95aca086716c155",
    "author": "",
    "url": "https://www.reuters.com/article/us-rigel-pharms-fda/fda-approves-rigel-pharmaceuticals-drug-for-rare-bleeding-disorder-idUSKBN1HO2TV",
    "ord_in_thread": 0,
    "title": "FDA approves Rigel Pharmaceuticals' drug for rare bleeding disorder",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Rigel Pharmaceuticals Inc’s treatment for a rare bleeding disorder.\nRigel’s Tavalisse was approved to treat patients with immune thrombocytopenic purpura, a disease characterized by excessive bruising and bleeding caused by unusually low levels of platelets, which are integral to clotting.\nReporting by Tamara Mathias in Bengaluru; Editing by Anil D'Silva\n ",
    "published": "2018-04-17T20:59:00.000+03:00",
    "crawled": "2018-04-17T21:12:46.026+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "reuters",
        "food",
        "drug",
        "administration",
        "tuesday",
        "approved",
        "rigel",
        "pharmaceutical",
        "inc",
        "treatment",
        "rare",
        "bleeding",
        "disorder",
        "rigel",
        "tavalisse",
        "approved",
        "treat",
        "patient",
        "immune",
        "thrombocytopenic",
        "purpura",
        "disease",
        "characterized",
        "excessive",
        "bruising",
        "bleeding",
        "caused",
        "unusually",
        "low",
        "level",
        "platelet",
        "integral",
        "clotting",
        "reporting",
        "tamara",
        "mathias",
        "bengaluru",
        "editing",
        "anil"
    ]
}